Brief: Cancer Genetics Posts Q4 Loss Per Share Of $0.14

Vyant Bio

01/06/2020 13:15

June 1 (Reuters) - Cancer Genetics Inc  CGIX.O :
    * CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019
FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES
    * Q4 LOSS PER SHARE $0.14
    * Q4 REVENUE ROSE 12 PERCENT TO $1.9 MILLION
    * CANCER GENETICS - CONTINUING TO EVALUATE POTENTIAL
STRATEGIC
OPTIONS INCLUDING COLLABORATIONS, MERGERS/ACQUISITIONS, OR OTHER
STRATEGIC TRANSACTIONS
    * CANCER GENETICS - FILED ANNUAL REPORT ON FORM 10-K FOR
YEAR
ENDED DEC 31, 2019 ON MAY 29TH WITH SECURITIES AND EXCHANGE
COMMISSION
    * CANCER GENETICS - 2019 AUDITED FINANCIAL STATEMENTS
CONTAIN
EXPLANATORY PARAGRAPH REGARDING CO'S ABILITY TO CONTINUE AS
GOING CONCERN
    * CANCER GENETICS - DISCLOSED IN FORM 10-K IT HAD CONCLUDED
INTERNAL CONTROLS OVER FINANCIAL REPORTING WAS INEFFECTIVE FOR
YEAR ENDED DEC 31, 2019
    * CANCER GENETICS - CONCLUSION OF INTERNAL CONTROLS OVER
FINANCIAL
REPORTING IN FORM 10-K RESULTED IN CO REPORTING DEFICIENCIES
CONSIDERED MATERIAL WEAKNESSES

Source text for Eikon:  ID:nGNXb7CFz1 
Further company coverage:  CGIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))